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INTRODUCTION
Immunotherapy for cancer has recently had several notable suc-
cesses in the context of both antigen specific,1,2 and antigen non-
specific,3 strategies. Such approaches rely upon the existence of 
tumor-associated proteins (TAP), against which T cell responses 
can be raised.4,5 In most cases, antitumor T cell responses require 
tolerance to self, or near self, proteins to be broken. Self-TAP may 
become immunogenic through overexpression, reactivation of 
expression, or abnormal processing on the target tumor cells.4 
Alternatively, novel immunogenic epitopes, potentially unique 
to each individual tumor, may be generated within otherwise 
self-TAP through translocations or by mutation.5,6 In times of 
cellular stress, such as infection, the proinflammatory Unfolded 
Protein Response (UPR) may also play a role in increased process-
ing of abnormal or aberrantly folded proteins.7–10 For example, 
ER stress is closely tied to levels of MHC Class I/II expression 
(reviewed in ref. 11). In addition, activation of the UPR through 
PERK-eIF2, can favor the translation of cryptic antigens which 
derive from initiation through CUG codons.12 Overall, activation 
of the UPR by both viral infection and by generation of abnor-
mally folded proteins can result in the presentation of an altered 
repertoire of antigens.
Even when T cells are present which can recognize self, or near 
self-TAP, tumors evolve rapidly away from the resultant immune 
pressure to generate antigen loss variants.13,14 Therefore, we and 
others have developed immunotherapies which seek to raise T cell 
responses against multiple antigens simultaneously.13,15,16 This strat-
egy is based upon the premise that no single cancer cell will be able 
to mutate sufficient number of cellular proteins concomitantly to 
evade a multispecific T cell response. In this respect, mice treated 
with the highly immunogenic platform of the Vesicular Stomatitis 
Virus (VSV) expressing a TAP cDNA library generated a CD4+ T cell 
dependent response against several different self-TAP, which, in 
combination, eradicated well-established tumors.15,16 Antitumor 
therapy was immune-mediated following systemic (intravenous) 
delivery of the library, and was effective against various different 
histological types of tumor using cDNA from the appropriate tissue 
source.15–18 In the case of a melanoma-derived VSV-cDNA library, a 
combination of 3 individual VSV - VSV-N-RAS, VSV-Cytochrome-C, 
and VSV-TYRP-1 (VSV-TAP)-treated established subcutaneous B16 
melanomas in C57BL/6 mice, almost as effectively as the overall, 
unfractionated VSV-cDNA library.16,17 This was associated with a 
CD4+ T cell dependent IL-17 response to B16 tumor cells but no 
detectable IFN-γ response.16,17
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We showed previously that therapy with Vesicular Stomatitis Virus (VSV) expressing tumor-associated proteins eradicates 
 established tumors. We show here that when cellular cDNA were cloned into VSV which retained their own poly-A signal, viral 
species emerged in culture which had deleted the cellular poly-A signal and also contained a truncated form of the protein 
coding sequence. Typically, the truncation occurred such that a Tyrosine-encoding codon was converted into a STOP codon. 
We believe that the truncation of tumor-associated proteins expressed from VSV in this way occurred to preserve the ability of 
the virus to replicate efficiently. Truncated cDNA expressed from VSV were significantly more effective than full length cDNA in 
treating  established tumors. Moreover, tumor therapy with truncated cDNA was completely abolished by depletion of CD4+ T cells, 
whereas therapy with full length cDNA was CD8+ T cell dependent. These data show that the type/potency of antitumor immune 
responses against self-tumor-associated proteins can be manipulated in vivo through the nature of the self protein (full length 
or truncated).  Therefore, in addition to generation of neoantigens through sequence mutation, immunological tolerance against 
self-tumor- associated proteins can be broken through manipulation of protein integrity, allowing for rational design of better 
 self- immunogens for cancer immunotherapy.
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In this study, we further characterized the cDNA inserts of 
this individual VSV-TAP16 to understand the mechanisms by 
which cumulatively they generate antitumor T cell responses. 
Interestingly, each of the TAPs encoded by the VSV were 
 truncated, but not mutated. When combined, the VSVs express-
ing full-length cDNAs induced a CD8-dependent antitumor 
response, while VSVs expressing truncated cDNA generated a 
CD4+ T cell dependent antitumor immune response. These data 
are highly significant for designing better immunogens based on 
self-TAP for cancer immunotherapy. In addition they may help 
to explain the etiology of infectious and autoimmune diseases, 
in which pathogenic infection and/or cellular stress, cause the 
aberrant folding of normal cellular proteins, leading to the gen-
eration of anti-self autoimmunity.19–22
Figure 1  Immunologically active VSV-TAP are deleted at the 3’ ends of the inserted cDNA. (a) Mice bearing 5-day-old s.c. B16 tumors were treated (n 
= 7–8/group) with nine i.v. injections on days 6–8, 13–15, and 20–22 with: a three-way combination (total viral dose 107 pfu/injection; 3 × 106 pfu of 
each virus) of VSV-TAP, the VSV-cDNA library (ASMEL), VSV-GFP (107pfu/injection), or PBS. The percentage of long term survivors (>60 days) for each 
treatment over three independent experiments is shown. (b) cDNA was initially inserted into the VSV genome pVSV-XN2 (ref. 23) between the Xho1 
and Nhe1 cloning sites between the G and L genes. cDNA containing 5′ and 3′UTR, the coding cDNA and the cellular poly A tail from human melanoma 
cells was initially cloned into the shuttle plasmid pSPORT6. These cDNA were transferred from the pSPORT6 plasmid into the pVSV-XN2 VSV genomic 
plasmid using PCR primers which recognized flanking pSPORT6 vector sequences (linker sequences) and the appropriate Xho1 and Nhe1 restriction 
sites. However, following virus production it was found that each of the immunogenic TAP was truncated at their C termini. (c) Schematic showing the 
sequencing results of each of the truncated VSV-TAP viruses from ASMEL. The terminal TAC tyrosine codon is converted to a TGA “stop” codon for each 
virus. (d-f) The C terminal sequences of the TAP found at the junction of cDNA and VSV sequences are shown for the d N-RAS. e CYT-C, and f TYRP-1 TAP. 
In each case the inserted cDNA sequence is underlined. In each case, a TAC codon (cDNA sequence, Tyrosine, Y) is mutated to TAG (STOP) converting a 
Tyrosine to a STOP (bolded); The 3′ C terminal N-RAS amino acids deleted are YRMKKLNSSDDGTQGCMGLPCVVM; the 3′ C terminal CYT-C amino acid 
sequences deleted are YTIKRHKWSVLKSRKLAYRPPK; and the 3′ C terminal TYRP-1 amino acids deleted are YQCYAEEYEKLQNPNQSVV. GCTAGC is the 
Nhe1 site in the VSV genome in the intergenic region between the G and L genes; TATGAAAAAAA is the intergenic VSV polyA sequence (italicized); CT 
is the intergenic dinucleotide between the G and L genes of VSV (italicized); AACAG is the intergenic VSV transcription start sequence; and the final ATG 
is the start codon of the L gene. ASMEL, altered-self melanoma; PBS, phosphate buffered saline; PCR, polymerase chain reaction; TAP, tumor-associated 
proteins; VSV, Vesicular Stomatitis Virus. 
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ReSUlTS
Therapeutically active cDNA expressed from VSV are truncated
Our previous work has shown that the combination of VSV-N-
RAS, VSV-Cytochrome C, and VSV-TYRP1 (VSV-TAP) mimics most 
of the therapeutic effects of treatment with the altered-self mela-
noma (ASMEL) TAP library against established B16 mouse tumors 
(Figure 1a).16 During the construction of the initial cDNA library, polyA-
containing cellular cDNAs were cloned into the VSV genomic plasmid 
(pXN2)23 using Xho1 and Nhe1 sites (Figure 1b). Sequencing of the cel-
lular cDNA contained in the VSV-N-RAS, VSV-Cytochrome C, and VSV-
TYRP1 revealed no mutations in the cDNA inserts. However, in each 
case, the cellular cDNA were truncated at their C-termini (Figure 1c). 
Although the deletions of the cellular sequences varied in length, the 
final amino acid that was lost in each case was a Tyrosine residue (TAC 
to TGA “stop” codon), which became juxtaposed with the first gua-
nine of the Nhe1 cloning site (Figure 1d–f). In addition to the loss of 
the C-termini of the proteins, the deletions also removed the cellular 
3′-untranslated (3′-UTR) and poly-A tails which were included from 
the initial method of cDNA library construction (Figure 1c).
Deletion of coding sequences and poly-A as a result of viral 
passage
To investigate the significance of these deletions in each of the VSV-
TAP recovered from the initial library, we constructed a VSV express-
ing only the full length cDNA of the N-RAS gene24 with no 3′UTR or 
cellular poly-A tail (VSV-cDNA-N-RAS) (Figure 2a). Following rescue 
of this virus from BHK cells, the full length N-RAS cDNA was retained 
through viral multiple passages (>10) as shown by polymerase 
chain reaction (PCR) (Figure 2b). Cells infected by the ASMEL VSV-
cDNA library predominantly expressed the deleted N-RAS encoded 
for by VSV-Δ-N-RAS (Figure 2b). These data show that the full-length 
coding region of the N-RAS cDNA, without a poly-A tail and 3′UTR 
can be carried as a stable insert through multiple passages in VSV.
The parental pXN2-cDNA plasmid library (that was used to cre-
ate the viral library) did not possess the 60 bp cDNA deletion found 
in the truncated VSV-Δ-N-RAS virus (Figure 2c,d). However, the 
sequence (linking the cDNA of N-RAS with the viral L gene) was 
deleted, including the 3′UTR region, in VSV recovered from cells 
infected with the ASMEL library (Figure 2c,d). This deletion also 
Figure 2 Characterization of VSV-TAP truncations. (a) Schematic of VSV-cDNA-N-RAS generated showing original cloned product and deleted sequence. 
Location of primers used for diagnostic PCRs are shown (arrows). (b) PCR product from BHK cells infected with viruses shown (MOI 0.1, 48 hours 
postinfection) using the primer pairs shown. (c) PCR product from the plasmid pXN2-cDNA library, which was used to generate the ASMEL VSV-cDNA 
library stocks, or (d) from cDNA of BHK cells infected with the ASMEL VSV-cDNA library (MOI 0.1, 24 hours postinfection) using the primer pairs as shown. 
(e) PCR from cDNA of BHK cells infected with the VSV-Δ-N-RAS or (f) VSV-GFP viruses (MOI 0.1, 24 hours postinfection) using the primer pairs as shown. 
(g) PCR from the pXN2-cDNA plasmid library (100 ng), the viruses listed (MOI 0.1, 24 hours postinfection), or from sham infected BHK cells using VSV-
G-specific primers. *Indicates a signal obtained using 40 cycles of amplification; †Indicates a signal obtained using 10 cycles of amplification (all others 
were 25 cycles). The size of PCR products which are predicted from the primer pairs following PCR from a nondeleted viral genome as in a are shown 
(bp = base pairs). ASMEL, altered-self melanoma; GFP, green fluorescence protein; MOI, multiplicity of infection; PBS, phosphate buffered saline; PCR, 
polymerase chain reaction; TAP, tumor-associated proteins; VSV, Vesicular Stomatitis Virus.
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included the cellular poly-A tail and plasmid linker sequences. No 
PCR products linking N-RAS cDNA and VSV-L protein sequences 
were detected from cells infected with the control VSV-GFP virus 
and cDNA for the VSV-G envelope protein was abundant in all cells 
infected with VSV (Figure 2e–g). Therefore, the deletion seen in the 
VSV-Δ-N-RAS virus was not present in the plasmid cDNA library, but 
resulted from passage of virus through cells.
To test the hypothesis that truncation seen in VSV-Δ-N-RAS was 
a result of incompatibility between retention of the cellular poly-A 
tail and normal viral transcription, we constructed VSVs expressing 
the human melanoma antigen hgp100 cDNA25 with, or without, 
a 3′UTR and a poly-A tail (Figure 3a). Following three passages of 
these viruses through BHK cells, 10 plaques of both viruses were 
isolated and sequenced. All of the VSV-hgp100 viruses expressing 
only the cDNA retained the full-length cDNA (Figure 3b). Half of 
the plaques from the serial passage of the VSV-hgp100-poly-A virus 
were truncated by 46 C terminal amino acids and two plaques were 
truncated by an additional 51 amino acids (Figure 3b). The remain-
ing 3 out of 10 plaques did not provide informative sequence. As in 
Figure 1 both truncations resulted in the generation of a new TGA 
stop codon that became juxtaposed with the Nhe1 site in the viral 
genome. Therefore, in two separate examples (VSV-N-RAS and VSV-
hgp100), multiple passages of a VSV-cDNA virus including a cellular 
poly-A tail led to its deletion and truncation of the encoded cDNA.
Therapeutic consequences of 3′ protein truncations
Intravenous injection of nine doses of VSV-Δ-hgp100 (46 amino acids 
deleted, generated from Figure 3b) was significantly more therapeutic 
against 5 day established B16 tumors than either VSV-cDNA-hgp100 
(not truncated) (P = 0.0137) or VSV-GFP (P = 0.0005) (Figure 3c).
We also engineered VSV expressing only the cDNA of the TYRP-1 
(ref. 26) or CYT-C (ref. 27) genes, with no 3′UTR or poly-A tail like the 
VSV-cDNA N-RAS described above. Together we will refer to these 
three viruses as VSV-cDNA-TAP. As described previously, between 
70–80% of mice with established 5 day B16 tumors were cured of 
their tumors by intravenous injection of nine doses of VSV-Δ-TAP 
(two separate experiments shown in Figure 4a–d). Although there 
was a significant prolongation of survival of mice treated with 
the  combination of VSV-cDNA-TAP compared with sham treated 
mice (P = 0.0013), only a single mouse had a durable response in the 
experiment of Figure 4a. Consistent with our previous findings15,16 
and in vitro findings, in vivo depletion showed that the therapeu-
tic effects of VSV-Δ-TAP were completely dependent upon CD4+ 
T cells, and, to a lesser extent, also dependent upon CD8+ T cells 
(Figure 4e). In contrast, depletion of CD8+ T cells completely abro-
gated the therapy of VSV-cDNA-TAP and CD4+ T cell depletion had 
no significant effect on therapy (Figure 4f ).
Truncated cDNA are also immunogenic in plasmid vectors
Finally, we investigated whether truncated cDNA were more 
immunogenic than full-length counterparts when expressed from 
another vector platform. The cDNA library used to create the ASMEL 
was initially cloned into a plasmid in which the CMV promoter 
drives expression of the full-length cDNA (pcDNA) (Figure 5a). PCR 
confirmed that the cDNA in this plasmid library were full length 
before being cloned into the VSV genome (Figure 2). We also gener-
ated a plasmid vector encoding truncated cDNA (pΔcDNA) by clon-
ing the full range of truncated cDNA, as expressed from the ASMEL, 
using real-time PCR from BHK cells infected by the VSV-cDNA library 
(Figure 5a). Truncation of individual cDNA (N-RAS and CYT-C), as 
they were expressed from the VSV-cDNA library (Figure 2), was con-
firmed by PCR (not shown).
Intradermal injections of either pcDNA or pΔcDNA into tumor 
bearing mice had no significant effect on tumor control (not 
shown). In contrast, the addition of CpG as an adjuvant to these 
plasmid injections uncovered significant antitumor activity of both 
Figure 3 Truncated hgp100 is a more potent antitumor therapeutic than the full-length hgp100. (a) The minimal cDNA of the human gp100 gene 
(VSV-cDNA-hgp100), or the same cDNA with its associated cellular poly-A tail (VSV-hgp100-poly-A), were cloned into the pXN2 plasmid, from which 
the corresponding viruses were generated. (b). The VSV-hgp100 and VSV-hgp100-poly-A viruses were passaged through BHK cells three times (100 µl 
of cell supernatants used to infect new BHK cells 48 hours following infection). About 10 plaques of each virus were picked and sequenced across 
the L and G genes. The number of plaques containing full-length or truncated proteins is shown along with the C-terminal amino acid sequence and 
the length of truncation. (c) Mice bearing 5-day-old established subcutaneous B16 tumors were treated (n = 7–8/group) as described in Figure 1 with 
the viruses shown (107 pfu/injection) or PBS. Percent overall survival is shown. PCR, polymerase chain reaction; PBS, phosphate buffered saline; VSV, 
Vesicular Stomatitis Virus.
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pcDNA and pΔcDNA (compared with pCMV-GFP + CpG) (Figure 5b). 
However, pΔcDNA + CpG was significantly better at prolonging 
survival than pcDNA + CpG (Figure 5b), confirming that antitumor 
immunity can be manipulated through the integrity of the proteins 
expressed from vectors other than just VSV.
DISCUSSION
Here, we show that VSV-mediated expression of truncated versions 
of otherwise normal self-proteins leads to a CD4+ T cell dependent 
immune response which is highly effective at rejecting established 
tumors. These findings will have considerable significance for the 
design of more effective cancer vaccines where the goal is to break 
tolerance to normal self-TAP.28,29
We built upon our previous observation that a combination of 
three different self-proteins, expressed from VSV was necessary 
and sufficient to generate rejection of established B16 tumors in 
C57BL/6 mice (Figure 1a). Sequencing of the inserts of these immu-
nogenically active viruses, compared with the parent plasmids from 
which the virus library was made, revealed that each one encoded 
a truncated version of the normal protein and that this truncation 
was not a result of the molecular construction of the library in the 
plasmid (Figure 2). The normal mechanism of VSV gene expression 
involves polymerase detachment mediated by viral poly-A tails 
followed by reinitiation between coding sequences.30,31 We have 
shown here that if a cellular poly-A tail is included in the transgene 
cloned into VSV (either multiple cDNA or hgp100), it is excised at 
high frequency from replicating clones of the virus. Our current 
hypothesis is that the viral polymerase interacts with the human 
poly-A tail in some way that promotes premature detachment from 
the viral template and interferes with the reattachment necessary 
to initiate transcription of the downstream (L) viral gene. However, 
exactly what the properties of the cellular poly-A tail sequences are 
that cause them to be so strongly selected against in replicating VSV 
remain to be elucidated. Consistent with this hypothesis, in vitro 
passage of the VSV-hgp100-poly-A virus generated progeny viruses 
in which the cDNA was truncated, with loss of the associated cel-
lular poly-A tails. In contrast, passage of the VSV-cDNA-hgp100 (no 
cloned poly-A), virus did not generate any truncations of the cDNA 
(Figure 3). We are currently investigating the mechanisms of how 
Figure 4 Truncated self-TAP generate long-lived protective antitumor therapy. (a) Mice bearing 5-day-old established s.c. B16 tumors were treated (n = 
7–8/group) with nine i.v. injections as in Figure 1 with the viruses shown. Survival with time is shown. (b–d) Mice bearing 5-day-old s.c. B16 tumors were 
treated with nine i.v. injections on days 6–8, 13–15, and 20–22 with b VSV-GFP (107pfu/injection), c VSV-cDNA-TAP (a three-way combination, total viral 
dose 107 pfu/injection; and 3 × 106 pfu of each virus) or with d VSV-Δ-TAP. Tumor volumes with time are shown. In general, tumors became palpable and 
either progressed without regression (VSV-GFP); plateaued and regressed with a later recurrence (VSV-cDNA-TAP, VSV-Δ-TAP) or plateaued, regressed 
and remained undetectable for the duration of the experiment (VSV-Δ-TAP). The experiment of a above was repeated, by treating 5-day-tumor bearing 
mice with (e) VSV-cDNA-TAP or (f) VSV- Δ-TAP with, or without, the depletion of CD8+ cells or CD4+ cells. GFP, green fluorescence protein; TAP, tumor-
associated proteins; VSV, Vesicular Stomatitis Virus.
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this deletion occurs. The repeated finding that the deletion is associ-
ated with a tyrosine residue suggests that recombination at specific 
bases within the cDNA coding sequence is important. Therefore, 
the method by which we initially constructed the cDNA library in 
VSV, by inclusion of cellular poly-A tails, led fortuitously to the emer-
gence of VSV-encoded self-TAP as truncated versions of the normal 
self-proteins.
We have shown in previous reports that both VSV-cDNA library 
and VSV-Δ-TAP therapy are dependent upon CD4+ T cells.15–18 Our 
data in Figure 4 are consistent with these findings, demonstrating 
that truncated and full length self-proteins skew the resultant anti-
tumor immune response toward CD4+ T cell dependent (truncated) 
or CD8+ T cell dependent (full length) responses (Figure 4). Although 
the same titers of VSV expressing full length and truncated versions 
of each TAP were used, we cannot exclude that differences in levels 
of TAP expression may occur in vivo in APC stimulated to present 
the different TAP. If so, expression levels may influence levels of TAP 
presentation and ultimate immunogenicity.
With either VSV- or plasmid- mediated delivery of truncated 
versions of normal self-TAP an intensive schedule of vaccination 
was required (nine i.v. injections of VSV or addition of CpG adju-
vant). We believe that the adjuvant activity of the innate immune 
activation induced by the VSV or CpG has dual anti-tumor effects. 
Systemic activation of innate immune effectors through VSV- or 
CpG- mediated TLR activation can lead to initial control of tumor 
growth consistent with our previous findings that VSV oncolytic 
therapy of B16 tumors requires innate immune effectors and 
Myd88 signaling.32,33 In addition, TLR activation leads to potent 
activation of APC in the lymph nodes in the presence of the 
codelivered TAP. The result is the combination of potent innate 
immune effector activation along with the priming of relatively 
weak antitumor T cell responses against self-TAP which are 
together able to clear established tumors.
Our current results also extend our previous work to show that this 
CD4+ T cell dependent response raised against truncated self-TAP 
was significantly more therapeutically potent than the CD8+ T cell 
dependent response raised against the corresponding full length 
self-TAP. In some respects, the superiority of the CD4+ T cell response 
against truncated antigens over the CD8+ T cell response against 
full length antigens appears to be counterintuitive. However, these 
results are consistent with reports that several types of autoimmune 
responses are often closely associated with CD4+ T cells.34,35 Since 
the antigenic targets against which antitumor immune responses 
are directed here are all derivatives of self-proteins, these antitumor 
responses are essentially autoimmune. Overall, these data suggest 
that strategies aimed at raising potent autoimmune, CD4+ T  cell 
dependent responses should be developed along with those tar-
geting more classical CD8+ T cell activation, especially when the 
antigenic targets are essentially self-proteins.
Taken together, our data show that the type and potency of antitu-
mor immune responses against self-TAP can be manipulated in vivo 
through the integrity of the self protein that is used (full length or 
truncated self-TAP) and the resultant skewing of the T cell response 
to either a CD8+ or a CD4+ phenotype. These results have broad and 
important implications for the future design of cancer vaccines used 
alone or in combination with further immune potentiators such as 
checkpoint inhibitors.3–5 Thus, we have shown that vaccines in which 
self-TAP are intentionally truncated may be significantly more potent 
than those using full length proteins and that the enhanced immuno-
genicity of these truncated proteins is not dependent upon the type 
of vector used (Figures 4 and 5). We are currently investigating the 
molecular basis of the different antitumor immune responses raised 
by truncated versus full-length self-proteins. In this respect, one pos-
sible hypothesis is that this increased immunogenicity is associated 
with the activation of the UPR by these truncated, and therefore, 
likely to be poorly folded proteins.7–10 VSV infection itself will activate 
Figure 5 Immunogenicity of truncated cDNA in plasmid vectors. (a) cDNA from 2 human melanoma cell lines was cloned into a CMV-expression vector 
to generate a plasmid cDNA library which included full length cDNA clones along with the cellular poly A (CpolyA). cDNA in this plasmid library (pcDNA) 
was confirmed to be nontruncated (Figure 2). This library was cloned into the VSV genomic plasmid pXN2, as previously described16,17 to generate the 
VSV library (ASMEL). Following passage through BHK cells, the now truncated cDNA library was cloned back into the parental plasmid using RT-PCR 
to generate the truncated plasmid library (pΔcDNA). The truncated cDNA were expressed from the plasmid using the SV40 poly A as shown. (b) Mice 
bearing 5-day-old established s.c. B16 tumors were treated (n = 7–8/group) with nine intradermal injections of pCMV-GFP, pcDNA, or pΔcDNA (10 
µg plasmid per injection) with 100 µg CpG per injection on days 6, 8, 10, 13, 15, 17, 20, 22, and 24. Survival of treated with mice with time is shown. 
Groups were compared using the log rank test. (**P < 0.01, ****P < 0.0001, n.s. = not significant.) Reprinted from refs. 16, 17 possibly with permission 
of publisher or organization. ASMEL, altered-self melanoma; GFP, green fluorescence protein; RT-PCR, reverse transcriptase polymerase chain reaction; 
TAP, tumor-associated proteins; VSV, Vesicular Stomatitis Virus.
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the UPR and so additional activation by poorly folded proteins may 
accentuate the immunogenicity of virally encoded TAP through 
directing appropriate epitopes into different pathways of antigen 
presentation and/or by triggering production of inflammatory 
cytokines. In addition, other pathways, such as the nonsense medi-
ated decay (NMD)-pathway may also be responsible for the altered 
antigen-presentation of these truncated self-proteins. It may also be 
observed that deletion of C terminal sequences of the TAP leads to 
the loss of important epitopes which mediate suppressive anti-TAP 
T cell responses.
This represents a new area for exploitation in the design of  cancer 
vaccines, in which generation of self-TAP immunogens based upon 
alterations in protein integrity may be complementary to those 
approaches based upon changes in neo-antigen expression and 
sequence mutation.3–5 Finally, our data here may have  considerable 
significance for understanding the etiology of autoimmune  diseases 
in which pathogen infection, stress, or trauma may activate the UPR, 
thereby triggering responses against self-antigen leading to auto-
immune pathologies.19–22
MATeRIAlS AND MeTHODS
Cells and viruses
Murine B16 F1 melanoma (H2-Kb) cells (American Type Culture Collection, 
Manassas, VA) were maintained as previously described and grown in 
Dulbecco’s modified Eagle’s medium (DMEM; Life Technologies, Carlsbad, 
CA) supplemented with 10% (v/v) fetal calf serum (FCS; Life Technologies) 
and L-glutamine (Life Technologies). All cell lines were routinely monitored 
and found to be free of Mycoplasma infection.
VSV-cDNA libraries were generated as previously described.15,16 Briefly, 
cDNA from human melanoma cell lines were pooled and cloned into the 
pCMV.SPORT6 cloning vector (Invitrogen, Carlsbad, CA) and amplified by 
PCR. The cDNA were then size fractionated to below 4 kbp for ligation 
into the parental VSV genomic plasmid, pVSV-XN2 (ref. 23), between the G 
and the L genes. Virus was generated from BHK cells by cotransfection of 
pVSV-XN2-cDNA library DNA along with plasmid encoding viral genes as 
described.23 Virus was expanded by infection of BHK cells and purified by 
sucrose gradient centrifugation.
VSV expressing individual cDNA (with or without the 3′UTR and poly-A 
tail of the gene) were generated by cloning the cDNA into the plasmid pVSV-
XN2, as described.15,16,23 Monoclonal VSV-cDNA were obtained by plaque 
purification on BHK-21 cells. Concentration and purification were done by 
sucrose gradient centrifugation. Titers were measured by standard plaque 
assays on BHK-21 cells.23
In vivo studies
All procedures were approved by the Mayo Foundation Institutional Animal Care 
and Use Committee. C57BL/6 mice were purchased from Jackson Laboratories 
(Bar Harbor, ME) at 6–8 weeks of age. To establish subcutaneous tumors, 2 × 105 
B16 cells in 100 μl of phosphate buffered saline (PBS) were injected into the 
flank of mice. Typically, these tumors became palpable within 5–7 days. For in 
vivo treatment protocols, C57Bl/6 mice bearing 5-day-old s.c. B16 tumors were 
treated (typically n = 7–8/group) with nine i.v. injections on days 6–8, 13–15, and 
20–22 of the viruses as described in the text. Total viral doses of 107 pfu/injection 
were used in 100 µl. For survival studies, tumor diameter in two dimensions was 
measured three times weekly using calipers and mice were killed when tumor 
size was ~1.0 × 1.0 cm in two perpendicular directions.
Immune cell depletions were done by intraperitoneal injections 
(0.1 mg per mouse) of anti-CD8 (Lyt 2.43), anti-CD4 (GK1.5), both from the 
Monoclonal Antibody Core Facility, Mayo Clinic; and IgG control (ChromPure 
Rat IgG, Jackson ImmunoResearch, West Grove, PA) at day 4 after tumor 
implantation and weekly thereafter.
Reverse transcriptase PCR
RNA was prepared from cell cultures with the Qiagen (Hilden, Germany) RNA 
extraction kit. About 1 μg total cellular RNA was reverse transcribed in a 20 
μl volume using oligo-(dT) as a primer. A cDNA equivalent of 1 ng RNA was 
amplified by PCR with gene specific primers.
Statistics
Survival data from the animal studies were analyzed using the log rank test. 
All statistical analysis was carried out in GraphPad Prism software (GraphPad 
Software, La Jolla, CA). Statistical significance was determined at the level 
of P < 0.05.
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